Elenestinib

DRUG3 trials

Sponsors

Blueprint Medicines Corp., Blueprint Medicines Corporation

Conditions

Healthy ParticipantsIndolent Systemic MastocytosisIndolent Systemic Mastocytosis and SSMSmoldering Systemic Mastocytosis

Phase 1

A Study of Elenestinib in Healthy Adult Female Participants

CompletedNCT07388511

Blueprint Medicines CorporationHealthy Participants

Start: 2026-02-05End: 2026-04-02Updated: 2026-04-20

Phase 2

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

RecruitingNCT04910685

Blueprint Medicines CorporationIndolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis

Start: 2021-11-30End: 2032-09-30Target: 534Updated: 2026-08-04

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

RecruitingCTIS2024-516728-32-00

Blueprint Medicines Corp.Indolent Systemic Mastocytosis and SSM

Start: 2021-10-29Target: 379Updated: 2026-01-26

Related Papers

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Blood2023-11-0215 citations

P1017: HARBOR: A PHASE 2/3 STUDY OF BLU-263 IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS AND MONOCLONAL MAST CELL ACTIVATION SYNDROME

HemaSphere2022-06-015 citations